Condition: Advanced Solid Tumors · Colorectal Cancer · Sponsor: Vividion Therapeutics, Inc.
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. VVD-133214 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR. By acting on WRN, VVD-133214 may be able to block the growth of these types of cancer.
This description comes directly from the study's public registry record.
Vividion Clinical Trial Call Center · 1+ 858-345-9752 (U.S. Only) · clinicaltrials@vividion.com
Always discuss trial participation with your own doctor first.
| City of Hope Cancer Center | Duarte, California, United States | Recruiting |
| City of Hope at Irvine Lennar | Irvine, California, United States | Recruiting |
| START Los Angeles | Los Angeles, California, United States | Not Yet Recruiting |
| Emory University School of Medicine | Atlanta, Georgia, United States | Recruiting |
| Norton Cancer Institute - MDC | Louisville, Kentucky, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Not Yet Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Not Yet Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Completed |
| Oklahoma University Health Sciences Center | Oklahoma City, Oklahoma, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06004245